Amgen Inc. (BIT:1AMGN)
Italy · Delayed Price · Currency is EUR | Market Cap | 207.84B +51.1% |
| Revenue (ttm) | 33.34B +9.1% |
| Net Income | 7.65B +32.1% |
| EPS | 14.09 +31.6% |
| Shares Out | n/a |
| PE Ratio | 27.16 |
| Forward PE | 18.25 |
| Dividend | 8.50 (2.37%) |
| Ex-Dividend Date | Aug 20, 2026 |
| Volume | 13 |
| Open | 359.90 |
| Previous Close | 368.15 |
| Day's Range | 358.60 - 359.90 |
| 52-Week Range | 249.30 - 382.95 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.
Financial numbers in USD Financial StatementsNews
Amgen price target lowered to $378 from $388 at Guggenheim
Guggenheim analyst Vamil Divan lowered the firm’s price target on Amgen (AMGN) to $378 from $388 and keeps a Neutral rating on the shares as the firm updated its model…
Amgen price target lowered to $415 from $450 at BMO Capital
BMO Capital lowered the firm’s price target on Amgen (AMGN) to $415 from $450 and keeps a Market Perform rating on the shares as part of a broader research note…
Amgen price target raised to $328 from $317 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Amgen (AMGN) to $328 from $317 and keeps an Underperform rating on the shares after updating estimates ahead of the…
Amgen price target lowered to $430 from $435 at Wells Fargo
Wells Fargo lowered the firm’s price target on Amgen (AMGN) to $430 from $435 following pipeline valuation updates, while keeping an Equal Weight rating on the shares. The firm expects…
Amgen price target raised to $470 from $430 at UBS
UBS raised the firm’s price target on Amgen (AMGN) to $470 from $430 and keeps a Buy rating on the shares. The firm previewed Q3 earnings for the U.S. pharma…
Amgen price target raised to $430 from $400 at RBC Capital
RBC Capital raised the firm’s price target on Amgen (AMGN) to $430 from $400 and keeps an Outperform rating on the shares as part of a broader research note adjusting…
Amgen price target raised to $440 from $400 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Amgen (AMGN) to $440 from $400 and keeps a Neutral rating on the shares. The consensus long thesis depends on recent commercial…
Amgen price target raised to $380 from $362 at Truist
Truist raised the firm’s price target on Amgen (AMGN) to $380 from $362 and keeps a Hold rating on the shares as part of a broader research note previewing Q3…
Amgen price target lowered to $359 from $362 at Morgan Stanley
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Amgen (AMGN) to $359 from $362 and keeps an Equal Weight rating on the shares. The firm adjusted its…
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
Amgen price target raised to $500 from $450 at Scotiabank
Scotiabank analyst Louise Chen raised the firm’s price target on Amgen (AMGN) to $500 from $450 and keeps an Outperform rating on the shares. The firm notes Amgen’s execution has…
Amgen price target raised to $500 from $450 at Scotiabank
Scotiabank analyst Louise Chen raised the firm’s price target on Amgen (AMGN) to $500 from $450 and keeps an Outperform rating on the shares.
Competitive profile of Amgen’s dazodalibep still ‘open question,’ says Citi
Citi says Amgen’s (AMGN) dazodalibep delivered “positive” Phase 3 results in systemic Sjogren’s, which reduces clinical risk for “a potentially underappreciated I&I asset.” However, several details th...
Amgen announces ‘positive’ results from Phase 3 OASIZ 301 study
Amgen (AMGN) announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjogren’s disease and moderate-to-severe systemic disease activity. The study met...
Amgen's autoimmune drug succeeds in late-stage trial
Amgen said on Tuesday its experimental drug to treat an autoimmune disease that attacks the body's moisture-producing glands met the main goal of reducing disease activity in a late-stage trial.
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity Results Support the Potential for a New, Highly Differentiated Treatment Option f...
Amgen Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Quarterly revenue exceeded $10 billion, driven by strong growth across key products and robust pipeline progress. Landmark clinical results and regulatory advances support future growth, while disciplined capital allocation and evolving DTC strategies position the business for long-term success.
Amgen to deploy Veeva Vault CRM globally
Veeva Systems (VEEV) announced that Amgen (AMGN) plans to deploy Veeva Vault CRM globally, building on a collaboration spanning more than a decade. “Moving to Vault CRM will help accelerate…
Amgen says FDA approves update to imdelltra Prescribing Information
Amgen (AMGN) announced that the U.S. FDA approved an update to the imdelltra Prescribing Information that substantially reduces the recommended monitoring time for the first two doses of treatment in…
FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
Update Supports Broader Access to IMDELLTRA in Community Settings for People Living with Extensive-Stage Small Cell Lung Cancer THOUSAND OAKS, Calif., Sept. 14, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN...
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness
Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.
Amgen Transcript: Wells Fargo 21st Annual Healthcare Conference
Quarterly revenues exceeded $10 billion, driven by strong growth across six key product areas and robust pipeline progress. Landmark clinical results for IMDELLTRA and TEZSPIRE, expanding biosimilar portfolio, and strategic focus on productivity and disciplined investment support a positive long-term outlook.
HSBC downgrades Amgen to Hold on fair value after re-rating
HSBC analyst Morten Herholdt last night downgraded Amgen (AMGN) to Hold from Buy with a price target of $425, down from $445. After re-rating on Amgen’s strong execution and positive…